Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 189

The DOI matches its Crossref record.

Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV‐1Mngp120, HIV‐1SF2Recombinant gp120, or Both Vaccines in Seronegative Adults

Open access
Clements‐Mann, Mary Lou, Weinhold, Kent, Matthews, Thomas J., Graham, Barney S., Gorse, Geoffrey J., Keefer, Michael C., McElrath, M. Juliana, Hsieh, Ray‐Hahn, Mestecky, Jiri, Zolla‐Pazner, Susan, Mascola, John, Schwartz, David, Siliciano, Robert, Corey, Lawrence, Wright, Peter F., Belshe, Robert, Dolin, Raphael, Jackson, Susan, Xu, Serena, Fast, Patricia, Walker, Mary Clare, Stablein, Don, Excler, Jean‐Louis, Tartaglia, James, Duliege, Anne‐Marie, Sinangil, Faruk, Paoletti, Enzo, the NIAID AIDS Vaccine Evaluation Group · 1998 · The Journal of Infectious Diseases

Abstract

A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 microg of HIV-1SF2 recombinant (r) gp120 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses. HIV-1MN and HIV-1SF2 neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8+ T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/515288

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 189

Metadata

Authors
Clements‐Mann, M. L., Weinhold, K., Matthews, T. J., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Hsieh, R., Mestecky, J., Zolla‐Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P. F., Belshe, R., Dolin, R., Jackson, S., Xu, S., Fast, P., Walker, M. C., Stablein, D., Excler, J., Tartaglia, J., Duliege, A., Sinangil, F., Paoletti, E., & the NIAID AIDS Vaccine Evaluation Group
Venue
The Journal of Infectious Diseases
Published
1998-05
Volume
177
Issue
5
Pages
1230-1246
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2099067260
Cited by
189
References
0
FWCI
6.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV‐1Mngp120, HIV‐1SF2Recombinant gp120, or Both Vaccines in Seronegative Adults. https://app.cochat.ai/papers/10.1086/515288
The paper
Clements‐Mann, M. L., Weinhold, K., Matthews, T. J., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Hsieh, R., Mestecky, J., Zolla‐Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P. F., Belshe, R., Dolin, R., Jackson, S., Xu, S., . . . the NIAID AIDS Vaccine Evaluation Group. (1998). Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV‐1Mngp120, HIV‐1SF2Recombinant gp120, or Both Vaccines in Seronegative Adults. The Journal of Infectious Diseases. https://doi.org/10.1086/515288

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.